Profound Medical Corp. filed a Form 8-K with the SEC on August 17, 2026, disclosing the resignation of Chief Financial Officer Rashed Dewan and the appointment of Matthew Sobczyk as Interim Chief Financial Officer, both effective August 14, 2026.

Key Highlights

  • New Interim CFO: Matthew Sobczyk, age 42 and a CPA, CA, was appointed Interim Chief Financial Officer by the Board of Directors effective August 14, 2026.
  • Sobczyk's base salary: The company disclosed an annual base salary of CAD 300,414.58, with a discretionary bonus target of 15% of base salary.
  • CFO resignation: Rashed Dewan resigned as Chief Financial Officer effective August 14, 2026.
  • Cash severance: According to the filing, the company will pay Dewan a cash severance payment of $375,000 under the Mutual Separation Agreement.
  • Benefits continuation: The company will pay employer contributions to maintain Dewan's employee benefits for 15 months following the separation date.
  • Contractor arrangement: Dewan will provide transition and advisory services as an independent contractor from August 17, 2026 through November 25, 2026, at a rate of CAD 200 per hour, with continued vesting of 20,000 restricted share units.
  • Sobczyk's tenure: Sobczyk has served in progressively senior financial leadership roles at Profound Medical since May 2017, most recently as Corporate Controller from March 2023 to August 2026.

Profound Medical's CFO Transition: Sobczyk Appointment and Dewan Separation Terms

Profound Medical Corp. (NASDAQ:PROF) disclosed through the filing that Matthew Sobczyk was appointed Interim Chief Financial Officer by the Board of Directors on August 14, 2026. Sobczyk, who holds a Bachelor of Arts (Honours Business Administration) from the Richard Ivey School of Business at Western University and earned his CPA, CA designation in Ontario, has been with the company since May 2017. He most recently served as Corporate Controller from March 2023 until his appointment, having previously held the roles of Assistant Corporate Controller from March 2021 to March 2023 and Manager, Accounting and Reporting from May 2017 to March 2021. Before joining Profound Medical, the filing states he spent over a decade in public accounting, audit, and advisory roles with Ernst and Young LLP and MNP LLP.

The filing states that Sobczyk's selection was "not pursuant to any arrangement or understanding between Mr. Sobczyk and any other person," and that there are no family relationships between him and any director or executive officer of the company, and no transactions that would require reporting under Item 404(a) of Regulation S-K.

Regarding the departure of Rashed Dewan, the company and Dewan entered into a Mutual Separation Agreement dated August 14, 2026. In addition to the $375,000 cash severance and 15 months of employer benefit contributions, the agreement provides that Dewan's vested stock options outstanding as of the separation date, granted under the Company's Second Amended and Restated Share Option Plan, will remain exercisable until the earlier of 12 months after the separation date or the options' applicable expiry date. The company will also reimburse Dewan for up to CAD 5,000 in reasonable legal fees incurred in connection with his review of the Separation Agreement. The filing notes that copies of the Separation Agreement and Contractor Services Agreement will be filed as exhibits to the company's Quarterly Report on Form 10-Q.

What Was Disclosed

The filing disclosed the resignation of CFO Rashed Dewan and the Board-approved appointment of Matthew Sobczyk as Interim CFO, both effective August 14, 2026, along with the financial terms of Dewan's separation and the new consulting arrangement.